{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104531","form_type":"8-K","ticker":"NUVL","cik":"0001861560","company_name":"Nuvalent, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.422053+00:00","generated_at":"2026-05-17T18:22:23.197993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvalent Q2 2025 net loss $99.7M; rolling NDA for zidesamtinib initiated","bullets":["Net loss $99.7M; R&D $80.9M, G&A $23.7M; cash $1.0B funding into 2028.","Rolling NDA for zidesamtinib (ROS1+ NSCLC) initiated; target completion Q3 2025; FDA RTOR pilot.","ALKAZAR Phase 3 of neladalkib (ALK+ NSCLC) dosed; topline TKI pre-treated data expected year-end 2025.","Preliminary data for neladalkib in ALK+ solid tumors at ESMO 2025 (Oct 17-21).","Jason Waters promoted to SVP Commercial; Christy Oliger appointed to board."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104531","json":"https://secwatch.observer/filing/0000950170-25-104531.json","markdown":"https://secwatch.observer/filing/0000950170-25-104531.md","text":"https://secwatch.observer/filing/0000950170-25-104531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/0000950170-25-104531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1861560/000095017025104531/nuvl-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:22:23.197993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}